Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine vs placebo + azacitidine in newly diagnosed higher-risk MDS
2020-000744-55Phase 3Unknown
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Venetoclax + azacitidine with Placebo + azacitidine (2 arms). Primary endpoints: Complete remission and Overall survival. Status: unknown.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2020-000744-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000744-55.